ClinicalTrials.gg
CompletedNCT02694822Updated Mar 17, 2025Results posted

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

A Phase 1/2 interventional study of Zalifrelimab in Advanced Solid Cancers and Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies, sponsored by Agenus Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by Agenus Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
89
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, Phase 1/2, multicenter study to evaluate the safety, pharmacokinetics, and pharmacodynamics of an anti-cytotoxic T lymphocyte-associated protein-4 (CTLA-4) human monoclonal antibody (zalifrelimab) in participants with advanced or refractory cancer and in participants who have progressed during treatment with a programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitor as their most recent therapy.

The phase 1 portion of the study has been completed; it enrolled adult participants with refractory, advanced cancer in a 3+3 dose escalation cohort.

The phase 2 portion consisted of 51 participants who progressed during treatment with an approved or investigational PD-1/PD-L1 inhibitor as their most recent therapy (2-6 weeks prior to first dose of study drug).

02

Conditions studied

  • Advanced Solid Cancers
  • Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies
03

In context

Lead sponsor

Agenus Inc. is the lead sponsor of 31 studies on the registry; 2 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 3 (27%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written .
  2. ≥18 years of age.
  3. Histological or cytological diagnosis of solid cancer or lymphoma that is considered incurable and without therapies with established benefit. is not necessary for participants with known prior diagnosis, and clinical or radiographic evidence of recurrence. For Phase 2 only: Participants who experienced documented disease progression during treatment with an approved or /PD-L1 inhibitor as their most recent therapy (2-6 weeks prior to first dose of study drug). This cohort includes participants with histological diagnoses of hepatocellular carcinoma (HCC) (not including atypical histology such as cholangiocarcinoma mix or fibrolamellar hepatocellular carcinoma) who experienced documented disease progression during treatment with an approved or investigational PD-1/PD-L1 inhibitor as their most recent therapy (2-6 weeks prior to first dose of study drug).
  4. (ECOG) score of 0 or 1.
  5. Participants in Phase 2 with HCC should have a score of A or B7 with no encephalopathy or ascites.
  6. ≥12 weeks.
  7. Adequate cardiac function ( [NYHA] class ≤II).
  8. Adequate organ function, defined as (ANC) ≥1,500×10\^6/liter (L), absolute lymphocyte count ≥500/cubic millimeters (mm\^3), ≥8.0 grams/deciliter (g/dL), and count ≥100,000×10\^6/mm\^3 without blood growth factors or without transfusions within 1 week of first dose. For participants in Phase 2 with HCC: Platelet count ≥60×10\^6/mm\^3 and ANC ≥1,000×10\^6/L are acceptable provided that the principal investigator assesses these abnormalities as due to liver disease.
  9. Adequate liver function, defined as (AST) and alanine aminotransferase (ALT) ≤2.5× institutional (ULN), and ≤1.5 milligrams/deciliter (mg/dL) × ULN. For participants in Phase 2 with HCC: AST and ALT ≤5 × ULN, bilirubin ≤2 mg/dL × ULN, and albumin ≥2.8 mg/dL.
  10. Adequate renal function, defined as estimated ≥50 milliliters/minute according to Cockcroft-Gault formula, or measured 24-hour creatinine clearance (or local institutional standard method).
  11. Adequate coagulation defined by (INR) or prothrombin time (PT) ≤1.5× ULN (unless the participant is receiving anticoagulant therapy); and activated partial thromboplastin time ≤1.5× ULN (unless the participant is receiving anticoagulant therapy). Participants in Phase 2 with HCC can have an INR ≤2.3× ULN. Note: Participants in Phase 2 with HCC and on anticoagulant treatment would have an assigned value of 1 point when scoring PT/INR so the overall Child-Pugh score is not adversely affected.
  12. Female participants of and fertile male participants must agree to use adequate or abstain from sexual activity from the time of consent through 90 days after the end of study drug. Adequate contraception includes condoms with contraceptive foam; oral, implantable, or injectable contraceptives; contraceptive patch; intrauterine device; diaphragm with spermicidal gel; or a sexual partner who is surgically sterilized or . Note: Abstinence is acceptable if this is the established and preferred contraception for the participant.
  13. In the expansion phase, all participants must provide a sufficient and adequate formalin-fixed paraffin embedded (FFPE) tumor tissue sample preferably collected after progression on the last therapy and/or collected at screening, if clinically feasible. If a recent biopsy is not available, an archival FFPE sample should be provided from a site not previously irradiated. If no tumor tissue is available, a fresh biopsy will be required if clinically feasible.

Exclusion criteria

Exclusion Criteria

  1. Other treated within the last 5 years, except in situ cervix carcinoma or non-melanoma skin cancer.
  2. Other form(s) of antineoplastic therapy anticipated during the period of the study.
  3. Previous severe reaction to another fully human monoclonal antibody or severe reaction to immuno-oncology agents, such as colitis or pneumonitis requiring treatment with .
  4. History of interstitial lung disease.
  5. Primary or secondary immunodeficiency, including disease, disease (including autoimmune endocrinopathies), or usage of immunosuppressive medications.

    Note: Participants with diabetes type 1, vitiligo, psoriasis, hypo-, or hyperthyroid disease not requiring immunosuppressive treatment are eligible. Participants with Type 2 diabetes mellitus are allowed.

  6. Participants with a known history of 1 and 2, human T lymphotropic virus 1.

    Participants in Phase 2 with HCC: Participants with active infection who are receiving effective antiviral therapy are permitted. Participants with active infection are allowed (antiviral therapy not required).

  7. Administration of anticancer medications or drugs within the following intervals before the first administration of study drug: a. ≤14 days for chemotherapy, targeted small molecule therapy, or radiation therapy. Participants must also not have had radiation pneumonitis as a result of treatment and cannot participate in the study if they are on chronic corticosteroids for radiation pneumonitis. A 1-week is permitted for palliative radiation to non-central nervous system (CNS) disease, with medical monitor approval.

    Note: Bisphosphonates and denosumab are permitted medications. b. ≤14 days for prior immunotherapy. Participants in the dose escalation cohorts are excluded if they have received prior , costimulatory agonists, or immune modulating therapy except as described below. Once a dose level is determined to be safe by the safety review committee, participants will be allowed to enroll in dose-level expansion cohorts if they have received other non-CTLA-4 targeting immunotherapies.

    c. Participants enrolling in Phase 2 must have cancer that has progressed after prior treatment with an approved or investigational PD-1/PD-L1 inhibitor as their most recent therapy (2-6 weeks prior to first dose of study drug). The minimum requirement of 2 weeks (14 days) from prior anti-PD-1/PD-L1 therapy is to allow resolution of any lower-grade (≤2) adverse events observed with the therapy. If the investigator feels the participant has tolerated prior anti-PD-1/PD-L1 therapy well, then treatment with study agent may begin sooner.

    d. ≤7 days for prior corticosteroid treatment, with the following exceptions:

    • Use of an inhaled or topical corticosteroid is permitted.
    • Corticosteroid premedication for radiographic imaging for dye allergies is permitted.
    • Use of physiologic corticosteroid replacement therapy may be approved after consultation with the medical monitor. e. ≤21 days for prior monoclonal antibody used for anticancer therapy, with the exception of denosumab. This does not apply to participants being enrolled in Phase 2, who have received a PD-1/PD-L1 inhibitor as their most recent therapy (2-6 weeks prior to first dose of study drug; see above).

      f. ≤7 days for immunosuppressive-based treatment for any reason, with the exceptions noted above for prior corticosteroid treatment (exclusion criterion d).

      g. ≤21 days or 5 half-lives before first dose of study treatment for all other investigational study drugs or devices. For investigational agents with long half- lives (for example, >5 days), enrollment before the fifth half-life requires medical monitor approval.

      h. For participants in Phase 2 with HCC \<6 weeks for prior locoregional therapy to the liver, for example, transcatheter chemoembolization, radiation, surgery, or radioembolization.

  8. Has not recovered to grade ≤1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapy.

    Note: Participants with grade ≤2 neuropathy and alopecia are an exception and may enroll.

  9. Uncontrolled infection or other serious medical illnesses.
  10. History or presence of an abnormal that, in the investigator's opinion, is .
  11. Any medical conditions that, in the opinion of the investigator, would preclude use of AGEN1884, including AGEN1884 hypersensitivity.
  12. Women who are pregnant or breastfeeding.
  13. Concurrent participation in other investigational drug trials.
  14. Has a CNS tumor, (es), and/or carcinomatous meningitis identified either on the baseline brain imaging obtained during the screening period or identified prior to consent. Note: Participants with history of that have been treated may participate provided they show evidence of stable supra-tentorial lesions are obtained after treatment to the brain metastases. These imaging scans should both be obtained ≥4 weeks apart). In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have returned to baseline or resolved. For individuals who received steroids as part of brain metastases treatment, steroids must be discontinued ≥7 days prior to first dose of study drug.
  15. For participants in Phase 2 with HCC, the following exclusions also apply:

    1. Recent encephalopathy episodes in the last 6 months.
    2. Recent (within the last 6 months) gastro-esophageal varices bleeding.
    3. Participant whose tumors have cardiac involvement, as determined by imaging.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Zalifrelimab

    Participants received zalifrelimab intravenously.

    Drug: Zalifrelimab

Interventions

  • An anti-CTLA-4 monoclonal antibody.

    Also known as: AGEN1884

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) of Zalifrelimab

    A DLT was defined as a Grade ≥3 adverse drug reaction (ADR), according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5, occurring in the DLT evaluation period (28 days after the initial administration of zalifrelimab). An ADR was defined as all noxious and unintended responses to a medicinal product, related to any dose.

    Time frame: Up to 28 days

  2. Phase 1 and Phase 2: Number of Participants Experiencing Any Treatment-related Adverse Events

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment. A treatment-related AE was one in which a causal relationship between the medicinal product and the AE was at least a reasonable possibility and could not be ruled out. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to 6 years

  3. Phase 1: Maximum Drug Concentration (Cmax) of Zalifrelimab

    Blood samples were collected at designated timepoints to characterize Cmax of serum zalifrelimab following IV infusion in participants with metastatic or locally advanced solid tumors. Data reported as micrograms/milliliter (ug/mL).

    Time frame: Day 1 of Cycle 1 (21 days/cycle)

  4. Phase 1: Area Under the Drug Concentration-time Curve From 0 to 21 Days (AUC0-21d) of Zalifrelimab

    Blood samples were collected at designated timepoints to characterize AUC0-21d of serum zalifrelimab following IV infusion in participants with metastatic or locally advanced solid tumors. Data reported as hour times ug/mL (hour\*ug/mL).

    Time frame: Day 1 of Cycle 1 (21 days/cycle)

Secondary outcomes

  1. Phase 1 and Phase 2: Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) as determined by radiographic disease assessments per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1). BOR was defined as the best response recorded from the start of treatment until disease progression/recurrence; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters. CR was defined as disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to 6 years

  2. Phase 1 and Phase 2: Disease Control Rate (DCR)

    DCR was defined as the percentage of participants who had a confirmed response (CR or PR) or stable disease (SD) without progressive disease (PD). SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study).

    Time frame: Up to 6 years

  3. Phase 1 and Phase 2: Duration of Response (DOR)

    DOR was defined as the interval from which the date measurement criteria were met for CR or PR (whichever was first recorded) until the earliest date of disease progression, as determined by investigator assessment of objective radiographic disease assessments per RECIST v1.1, or death due to any cause, if occurring sooner than progression.

    Time frame: Up to 6 years

  4. Phase 1: Progression-free Survival (PFS)

    PFS was defined as the interval from the date of first dose of investigational agent until the earliest date of PD, as determined by independent endpoint review committee assessment of objective radiographic disease assessments per RECIST v1.1, or death due to any cause if occurring sooner than progression.

    Time frame: Up to 6 years

  5. Phase 2: PFS

    PFS was defined as the interval from the date of first dose of investigational agent until the earliest date of PD, as determined by independent endpoint review committee assessment of objective radiographic disease assessments per RECIST v1.1, or death due to any cause if occurring sooner than progression.

    Time frame: Up to 6 years

  6. Phase 1: Overall Survival (OS)

    OS was defined as the interval from the date of first dose of investigational agent until the date of death. For participants who did not die, OS was censored at last contact date.

    Time frame: Up to 6 years

  7. Phase 2: OS

    OS was defined as the interval from the date of first dose of investigational agent until the date of death. For participants who did not die, OS was censored at last contact date.

    Time frame: Up to 6 years

07

Results

Posted Mar 17, 2025

Participant flow

Phase 1
Participant flow — Phase 1
MilestonePhase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5Phase 2: Zalifrelimab
Started53101550
Received at least 1 dose of study drug53101550
Completed100110
Not completed43101440
Withdrew: Death216630
Withdrew: Withdrawal by subject224810
Phase 2
Participant flow — Phase 2
MilestonePhase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5Phase 2: Zalifrelimab
Started0000051
Received at least 1 dose of study drug0000051
Completed000008
Not completed0000043
Withdrew: Death0000026
Withdrew: Withdrawal by subject0000013
Withdrew: Administrative study closure000002
Withdrew: Lost to follow-up000001
Withdrew: Participant transferred to another site000001

Outcome measures

PrimaryPhase 1: Number of Participants With Dose-limiting Toxicities (DLTs) of Zalifrelimab

A DLT was defined as a Grade ≥3 adverse drug reaction (ADR), according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5, occurring in the DLT evaluation period (28 days after the initial administration of zalifrelimab). An ADR was defined as all noxious and unintended responses to a medicinal product, related to any dose.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) of Zalifrelimab
ParticipantsPhase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5
Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) of Zalifrelimab00000
PrimaryPhase 1 and Phase 2: Number of Participants Experiencing Any Treatment-related Adverse Events

An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment. A treatment-related AE was one in which a causal relationship between the medicinal product and the AE was at least a reasonable possibility and could not be ruled out. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to 6 years
Reported as:
Count of participants · Participants
Phase 1 and Phase 2: Number of Participants Experiencing Any Treatment-related Adverse Events
ParticipantsPhase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5Phase 2: Zalifrelimab
Phase 1 and Phase 2: Number of Participants Experiencing Any Treatment-related Adverse Events32612431
PrimaryPhase 1: Maximum Drug Concentration (Cmax) of Zalifrelimab

Blood samples were collected at designated timepoints to characterize Cmax of serum zalifrelimab following IV infusion in participants with metastatic or locally advanced solid tumors. Data reported as micrograms/milliliter (ug/mL).

Time frame:
Day 1 of Cycle 1 (21 days/cycle)
Reported as:
Median · ug/mL
Phase 1: Maximum Drug Concentration (Cmax) of Zalifrelimab
ug/mLPhase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5
Phase 1: Maximum Drug Concentration (Cmax) of Zalifrelimab1.95 ± 0.309467.15 ± 1.363523.1 ± 1.289163.5 ± 9.4314120 ± 18.075
PrimaryPhase 1: Area Under the Drug Concentration-time Curve From 0 to 21 Days (AUC0-21d) of Zalifrelimab

Blood samples were collected at designated timepoints to characterize AUC0-21d of serum zalifrelimab following IV infusion in participants with metastatic or locally advanced solid tumors. Data reported as hour times ug/mL (hour\*ug/mL).

Time frame:
Day 1 of Cycle 1 (21 days/cycle)
Reported as:
Median · hour*ug/mL
Phase 1: Area Under the Drug Concentration-time Curve From 0 to 21 Days (AUC0-21d) of Zalifrelimab
hour*ug/mLPhase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5
Phase 1: Area Under the Drug Concentration-time Curve From 0 to 21 Days (AUC0-21d) of Zalifrelimab317 ± 51.8971522 ± 246.423915 ± 964.8911390 ± 964.8918803 ± 2370.77
SecondaryPhase 1 and Phase 2: Objective Response Rate (ORR)

ORR was defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) as determined by radiographic disease assessments per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1). BOR was defined as the best response recorded from the start of treatment until disease progression/recurrence; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters. CR was defined as disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Up to 6 years
Reported as:
Number · percentage of participants
Phase 1 and Phase 2: Objective Response Rate (ORR)
percentage of participantsPhase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5Phase 2: Zalifrelimab
Phase 1 and Phase 2: Objective Response Rate (ORR)20.0 (0.5 to 71.6)0 (0.0 to 70.8)0 (0.0 to 30.9)0 (0.0 to 21.8)0 (0.0 to 52.2)5.9 (2.0 to 15.9)
SecondaryPhase 1 and Phase 2: Disease Control Rate (DCR)

DCR was defined as the percentage of participants who had a confirmed response (CR or PR) or stable disease (SD) without progressive disease (PD). SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study).

Time frame:
Up to 6 years
Reported as:
Number · percentage of participants
Phase 1 and Phase 2: Disease Control Rate (DCR)
percentage of participantsPhase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5Phase 2: Zalifrelimab
Phase 1 and Phase 2: Disease Control Rate (DCR)20.0 (0.5 to 71.6)33.3 (0.8 to 90.6)0 (0.0 to 30.9)6.7 (0.2 to 32.0)0 (0.0 to 52.2)37.3 (25.3 to 51.0)
SecondaryPhase 1 and Phase 2: Duration of Response (DOR)

DOR was defined as the interval from which the date measurement criteria were met for CR or PR (whichever was first recorded) until the earliest date of disease progression, as determined by investigator assessment of objective radiographic disease assessments per RECIST v1.1, or death due to any cause, if occurring sooner than progression.

Time frame:
Up to 6 years
Reported as:
Median · weeks
Phase 1 and Phase 2: Duration of Response (DOR)
weeksPhase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5Phase 2: Zalifrelimab
Phase 1 and Phase 2: Duration of Response (DOR)NA (NA to NA)————NA (NA to NA)
SecondaryPhase 1: Progression-free Survival (PFS)

PFS was defined as the interval from the date of first dose of investigational agent until the earliest date of PD, as determined by independent endpoint review committee assessment of objective radiographic disease assessments per RECIST v1.1, or death due to any cause if occurring sooner than progression.

Time frame:
Up to 6 years
Reported as:
Median · weeks
Phase 1: Progression-free Survival (PFS)
weeksPhase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5
Phase 1: Progression-free Survival (PFS)NA (3.143 to NA)11.000 (4.429 to NA)10.429 (5.286 to 12.429)11.143 (7.143 to 16.286)5.714 (2.571 to NA)
SecondaryPhase 2: PFS

PFS was defined as the interval from the date of first dose of investigational agent until the earliest date of PD, as determined by independent endpoint review committee assessment of objective radiographic disease assessments per RECIST v1.1, or death due to any cause if occurring sooner than progression.

Time frame:
Up to 6 years
Reported as:
Median · months
Phase 2: PFS
monthsPhase 2: Zalifrelimab
Phase 2: PFS2.0 (1.4 to 2.9)
SecondaryPhase 1: Overall Survival (OS)

OS was defined as the interval from the date of first dose of investigational agent until the date of death. For participants who did not die, OS was censored at last contact date.

Time frame:
Up to 6 years
Reported as:
Median · weeks
Phase 1: Overall Survival (OS)
weeksPhase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5
Phase 1: Overall Survival (OS)NA (17.429 to NA)71.143 (NA to NA)20.429 (2.000 to 49.857)70.571 (9.857 to NA)15.000 (4.857 to NA)
SecondaryPhase 2: OS

OS was defined as the interval from the date of first dose of investigational agent until the date of death. For participants who did not die, OS was censored at last contact date.

Time frame:
Up to 6 years
Reported as:
Median · months
Phase 2: OS
monthsPhase 2: Zalifrelimab
Phase 2: OS16.8 (5.7 to 25.6)

Adverse events

Collected over From Day 1 to the end of study (6 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Zalifrelimab Dose 12/5 (40%)2/5 (40%)5/5 (100%)
Phase 1: Zalifrelimab Dose 21/3 (33.3%)2/3 (66.7%)3/3 (100%)
Phase 1: Zalifrelimab Dose 36/10 (60%)5/10 (50%)10/10 (100%)
Phase 1: Zalifrelimab Dose 46/15 (40%)9/15 (60%)15/15 (100%)
Phase 1: Zalifrelimab Dose 53/5 (60%)3/5 (60%)5/5 (100%)
Phase 2: Zalifrelimab26/51 (51%)23/51 (45.1%)48/51 (94.1%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventPhase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5Phase 2: Zalifrelimab
GastroenteritisInfections and infestations0/51/30/100/150/50/51
DyspnoeaRespiratory, thoracic and mediastinal disorders0/51/30/101/150/52/51
Abdominal painGastrointestinal disorders0/50/31/100/151/51/51
Oesophagael obstructionGastrointestinal disorders0/50/30/100/151/50/51
VomitingGastrointestinal disorders0/50/30/100/151/50/51
SepsisInfections and infestations0/50/32/100/150/51/51
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/50/30/100/151/50/51
AstheniaGeneral disorders1/50/30/100/150/50/51
General physical health deteriorationGeneral disorders0/50/30/100/151/50/51
HyperbilirubinaemiaHepatobiliary disorders1/50/30/100/150/50/51
Most frequent other events
Showing 10 of 172
Most frequent other events
EventPhase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5Phase 2: Zalifrelimab
FatigueGeneral disorders0/51/35/109/154/517/51
DiarrhoeaGastrointestinal disorders1/52/32/107/152/513/51
VomitingGastrointestinal disorders3/52/34/106/151/59/51
DehydrationMetabolism and nutrition disorders0/52/32/103/150/52/51
NauseaGastrointestinal disorders1/51/34/105/153/514/51
ConstipationGastrointestinal disorders1/51/34/105/153/511/51
Abdominal painGastrointestinal disorders3/50/31/103/151/58/51
Chest painGeneral disorders2/50/30/101/150/50/51
Non-cardiac chest painGeneral disorders0/50/30/100/152/50/51
Blood creatinine increasedInvestigations0/51/32/106/151/55/51

Baseline characteristics

Safety Analysis Set: all participants who received at least 1 dose of zalifrelimab.

Age, Categorical
Age, Categorical(Participants)Phase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5Phase 2: ZalifrelimabTotal
<=18 years0000000
Between 18 and 65 years526753055
>=65 years014802134
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5Phase 2: ZalifrelimabTotal
Female227831941
Male313723248
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5Phase 2: ZalifrelimabTotal
Hispanic or Latino11340514
Not Hispanic or Latino4271154473
Unknown or Not Reported0000022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1: Zalifrelimab Dose 1Phase 1: Zalifrelimab Dose 2Phase 1: Zalifrelimab Dose 3Phase 1: Zalifrelimab Dose 4Phase 1: Zalifrelimab Dose 5Phase 2: ZalifrelimabTotal
American Indian or Alaska Native0000000
Asian1003059
Native Hawaiian or Other Pacific Islander0000000
Black or African American0012058
White439953969
More than one race0000000
Unknown or Not Reported0001023
08

Study locations

11 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • Comprehensive Cancer Center of Northwestern University
    Chicago, Illinois 60611, United States
  • Ochsner Cancer Institute
    New Orleans, Louisiana 70121, United States
  • Atlantic Health System/Morristown Medical Center
    Morristown, New Jersey 07962, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • Texas Oncology - Austin Midtown
    Austin, Texas 78705, United States
  • Texas Oncology, Tyler Texas
    Tyler, Texas 75702, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2016 to primary completion in Mar 2022, 71 months.

Results were first posted in Mar 2025, 2 years 11 months after primary completion. A results delay was requested in Feb 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2016
First posted
Mar 1, 2016
StartActual
Apr 2016
Primary completionActual
Mar 30, 2022
CompletionActual
Mar 31, 2022
Results delay requested
Feb 21, 2023
Results first posted
Mar 17, 2025
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02694822
Lead sponsor
Agenus Inc.
Responsible party
Sponsor
First posted
Mar 1, 2016
Start date
Apr 2016
Primary completion
Mar 30, 2022
Completion
Mar 31, 2022
Results posted
Mar 17, 2025
Last update
Mar 17, 2025

Study contacts

Medical Director
study director · Agenus Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zalifrelimab

Start the discussion